| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Lung Cancer |
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Key Words. Epidermal growth factor receptor • Non-small cell lung cancer • Tyrosine kinase
Correspondence: Correspondence: Lecia V. Sequist, M.D., M.P.H., Massachusetts General Hospital Cancer Center, 32 Fruit Street, Yawkey Suite 7B, Boston, Massachusetts 02114, USA. Telephone: 617-726-7812; Fax: 617-726-0453; e-mail: lvsequist{at}partners.org
Inhibiting epidermal growth factor receptor (EGFR) signaling has proven to be an effective strategy for treating non-small cell lung cancer (NSCLC) patients and the first generation of agents developed for this purpose, gefitinib and erlotinib, stimulated a unique escalation in both biologic and clinical research within the field. Second-generation EGFR-targeted agents that aim to further improve patient outcomes are now in preclinical and clinical trials. This review discusses four promising agents that are currently being studied in NSCLC: EKB-569, HKI-272, CI-1033, and ZD6474.
Disclosure of potential conflicts of interest is found at the end of this article.
This article has been cited by other articles:
![]() |
B. A. Teicher Newer Cytotoxic Agents: Attacking Cancer Broadly Clin. Cancer Res., March 15, 2008; 14(6): 1610 - 1617. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K.-K. Wong, M. Meyerson, and M. J. Eck The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP PNAS, February 12, 2008; 105(6): 2070 - 2075. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |